Added to YB: 2026-10-09
Pitch date: 2026-10-04
ZNTL [bullish]
Zentalis Pharmaceuticals, Inc.
-16.73%
current return
Author Info
No bio for this author
Company Info
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.
Market Cap
$252.8M
Pitch Price
$2.69
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.80
P/E
-1.37
EV/Sales
N/A
Sector
Biotechnology
Category
growth
M&A Hunter Portfolio Update: Tier 3 Core Convictions (Under $10) - Zentalis Pharmaceuticals, Inc.
ZNTL (hold): Zentalis is essentially azenosertib, an oral WEE1 inhibitor targeting Cyclin E1-high platinum-resistant ovarian cancer. The strategic case is a biomarker-defined gynecologic-oncology asset that could interest a franchise already serving this subgroup, but WEE1’s historical toxicity challenges remain central. The position stays satellite-sized until genomic-selection data clearly demonstrate both activity and a manageable safety profile.
Read full article (1 min)